Rapport Therapeutics Stock

rapportrx.comHealthcare / Healthcare softwareFounded: 2022Funding to Date: $250.18MM

Rapport Therapeutics is discovering and developing novel therapies targeting G protein-coupled receptors (GPCRs)

Register for Details

For more details on financing and valuation for Rapport Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Rapport Therapeutics.

Register Today

Other companies like Rapport Therapeutics in the Healthcare software sector

Sector
Last Round Est. Valuation
$656.14MM
Sector
Last Round Est. Valuation
$1.22B
Sector
Last Round Est. Valuation
$977.06MM
Sector
Last Round Est. Valuation
$6.1B
Sector
Last Round Est. Valuation
$402.35MM
Sector
Last Round Est. Valuation
$962.09MM
Sector
Last Round Est. Valuation
$742.72MM
Sector
Last Round Est. Valuation
$920.88MM